Phenotype of T cells in ChAglyCD3- and placebo-treated patients. (A) Median percentages of CD45RO⁺, CD45RO⁺CD27⁺, and CD45RA⁺CD45RO⁺ cells among CD8⁺ T cells in ChAglyCD3-treated (■) and placebo-treated (□) patients. (B) Flow cytometric analysis of CD45RA and CD45RO expression on gated CD8⁺ T cells in a representative ChAglyCD3-treated patient (ID157) on day 0 (left) and day 28 (right) after antibody therapy. (C) Mean percentages of CD4⁺ (left) and CD8⁺ (right) T cells expressing CD69, CD25, and HLA-DR in ChAGlyCD3- (■) and placebo-treated (□) patients up to month 12. *P < .05, **P < .001, ***P < .001 (comparison between ChAGlyCD3- and placebo-treated patients at each time point). (D) Mean (±SEM) serum concentrations of TNF-α, IL-6, IL-10, and IFN-γ at baseline (day 0) and after the first antibody infusion (T + 60 minutes for TNF-α, T + 240 minutes for IL-6, IL-10, and IFN-γ) in patients treated either with ChAGlyCD3 (■) or placebo (□). In panels A and C, the duration of ChAGlyCD3 therapy is represented by ↔.